Effectiveness of lorlatinib in advanced anaplastic lymphoma kinase-positive lung cancer
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib. ...
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib. ...
1. A deep-learning network using chest radiographs and basic demographic information was able to predict lung cancer incidence similar to ...
1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded ...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in ...
1. In this study comparing three prominent lung cancer screening strategies, all were found to be cost-effective, yielding incremental cost-effectiveness ...
1. In this modelling study, life-gained-based selection of smokers for lung cancer screening resulted in a nearly threefold greater gain ...
The following study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Radiology: Summaries of Clinically Relevant ...
1. Prediction tool may help physicians better personalize screening discussions with patients. 2. Benefits of the prediction tool, low-dose computer ...
1. In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.